According to the US Food and Drug Administration’s (USFDA) most recent enforcement notice, Aurobindo Pharma’s US-based arm is recalling 1,15,776 bottles of Moxifloxacin Ophthalmic Solution, an antibiotic used to treat bacterial infections.

Aurobindo Pharma and Sun Pharmaceutical Industries, two of India’s largest pharmaceutical companies, are recalling a variety of goods in the US market owing to deviations from acceptable manufacturing practises.

According to the US Food and Drug Administration’s (USFDA) most recent enforcement notice, Aurobindo Pharma’s US arm is recalling 1,15,776 bottles of Moxifloxacin Ophthalmic Solution, an antibiotic used to treat bacterial infections.

Aurobindo Pharma USA Inc, based in Princeton, is recalling the concerned batch owing to “failed impurities/degradation requirements,” according to the USFDA.

On January 14, this year, the business issued a countrywide Class II recall.

The USFDA has issued a recall for 59,232 bottles of Chlorthalidone tablets, which are used to reduce excess fluid levels in the body.

Sun Pharma Inc. of New Jersey is recalling the concerned batch due to “foreign substance identified as stainless steel microscopic wear particles combined with punch lubricating oil and silicone particles from the dust cup,” according to the US Food and Drug Administration.

On February 7, 2022, the business issued a Class II voluntary recall.

According to the USFDA, a Class II recall is launched when the use or exposure to a violative product may produce transitory or medically reversible adverse health effects, or when the risk of major adverse health effects is low.

The generic medication market in the United States was anticipated to be worth roughly USD 115.2 billion in 2019, according to industry estimates.